Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

This season’s vaccine is tailored to the SARS-CoV-2 XBB.1.5 sublineage and indicated as a single dose for most individuals 5 years of age and older Pre-clinical data show that the updated COVID-19 vaccine generates improved neutralizing...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news